Among 235 patients with CML we reviewed 91 patients with BC diagnosed
between 1980 and 1995; 15 of the 91 (16%) developed extramedullary dis
ease (EMD). The sites involved were the lymph nodes (13/15), CNS (1/15
) and suborbital mass (1/15). The appearance of EMD was associated wit
h chronic phase (CP) features in the bone marrow in 3/15 cases, with a
ccelerated phase (AP) in 3/15 and with BC in 9/15. 11/15 (73%) cases o
f EMD were classified as myeloid (My-EMD) and 4/15 as lymphoid-type (L
y-EMD): three B-phenotype and one T-phenotype. All Ly-EMD cases were t
reated with vincristine, daunorubicin and prednisone and obtained comp
lete remission (CR). Cases of My-EMD were treated with daunorubicin an
d cytosine arabinoside, of which only 1/11 achieved CR. We suggest tha
t in EMD also, the type, lymphoid or myeloid, of BC has a bearing on t
reatment response and prognosis: Ly-EMD is more responsive to treatmen
t and has longer survival than My-EMD. Copyright (C) 1996 Elsevier Sci
ence Ltd